Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation

被引:22
|
作者
Bastidas-Mora, Gabriela [1 ,2 ]
Bea, Silvia [1 ,2 ,3 ,4 ,5 ]
Navarro, Alba [3 ,5 ]
Gine, Eva [1 ,2 ,3 ,5 ]
Costa, Dolors [1 ,2 ,3 ,5 ]
Delgado, Julio [1 ,2 ,3 ,5 ]
Baumann, Tycho [1 ,2 ,5 ,6 ]
Magnano, Laura [1 ,2 ,3 ]
Rivas-Delgado, Alfredo [1 ,2 ,3 ]
Villamor, Neus [1 ,2 ,3 ,5 ]
Colomer, Dolors [1 ,2 ,3 ,4 ,5 ]
Lopez-Guerra, Monica [1 ,2 ,3 ,5 ]
Rozman, Maria [1 ,2 ,3 ]
Balague, Olga [1 ,2 ,3 ,5 ]
Martinez, Daniel [1 ,2 ,5 ]
Baptista, Maria Joao [7 ]
Escoda, Lourdes [8 ]
Alcoceba, Miguel [5 ,9 ]
Blanes, Margarita [10 ]
Climent, Fina [11 ]
Campo, Elias [1 ,2 ,3 ,4 ,5 ]
Wotherspoon, Andrew [12 ]
Lopez-Guillermo, Armando [1 ,2 ,3 ,4 ,5 ]
Matutes, Estella [1 ,2 ]
机构
[1] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain
[2] Hosp Clin Barcelona, Hematopathol Sect, Pathol Dept, Barcelona, Spain
[3] Inst Invest Biomed August Pi i Sunyer IDIBAP, Barcelona, Spain
[4] Univ Barcelona, Barcelona, Spain
[5] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
[6] Hosp 12 Octubre, Serv Hematol, Madrid, Spain
[7] Josep Carreras Leukaemia Res Inst IJC, ICO Hosp Germans Trias & Pujol, Barcelona, Spain
[8] ICO Hosp Joan XXIII, Tarragona, Spain
[9] Univ Hosp Salamanca HUS IBSAL, Dept Hematol, Canc Res Inst Salamanca IBMCC USAL CSIC, Salamanca, Spain
[10] Hosp Gen Univ Elda, Alicante, Spain
[11] Hosp Univ Bellvitge IDIBELL, Dept Pathol, Barcelona, Barcelona, Spain
[12] Royal Marsden NHS Fdn Trust, London, England
关键词
splenic marginal zone lymphoma; histological transformation; complex karyotype; prognostic factors; survival; B-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; VILLOUS LYMPHOCYTES; RESPONSE CRITERIA; RISK; RITUXIMAB; SURVIVAL; SPLENECTOMY; MULTICENTER; SERIES;
D O I
10.1111/bjh.17815
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe 36 patients with splenic marginal zone lymphoma (SMZL) with transformation (SMZL-T), including 15 from a series of 84 patients with SMZL diagnosed at the Hospital Clinic of Barcelona (HCB) and 21 diagnosed with SMZL-T in other centres. In the HCB cohort, the cumulative incidence of transformation at 5 years was 15%. Predictors for transformation were cytopenias, hypoalbuminaemia, complex karyotype (CK) and both the Intergruppo Italiano Linfomi (ILL) and simplified Haemoglobin, Platelet count, lactate dehydrogenase (LDH) and extrahilar Lymphadenopathy (HPLL)/ABC scores (P < 0 center dot 05). The only independent predictor for transformation in multivariate analysis was CK [hazard ratio (HR) 4 center dot 025, P = 0 center dot 05]. Patients with SMZL-T had a significantly higher risk of death than the remainder (HR 3 center dot 89, P < 0 center dot 001). Of the 36 patients with SMZL-T, one developed Hodgkin lymphoma and 35 a diffuse large B-cell lymphoma, 71% with a non-germinal centre phenotype. The main features were B symptoms, lymphadenopathy, and high serum LDH. CK was observed in 12/22 (55%) SMZL-T and fluorescence in situ hybridisation detected abnormalities of MYC proto-oncogene, basic helix-loop-helix transcription factor (MYC), B-cell leukaemia/lymphoma 2 (BCL2) and/or BCL6 in six of 14 (43%). In all, 21 patients received immunochemotherapy, six chemotherapy, one radiotherapy and three splenectomy. The complete response (CR) rate was 61% and the median survival from transformation was 4 center dot 92 years. Predictors for a worse survival in multivariate analysis were high-risk International Prognostic Index (HR 5 center dot 294, P = 0 center dot 016) and lack of CR (HR 2 center dot 67, P < 0 center dot 001).
引用
收藏
页码:146 / 155
页数:10
相关论文
共 50 条
  • [31] Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment
    Lenglet, Julien
    Traulle, Catherine
    Mounier, Nicolas
    Benet, Claire
    Munoz-Bongrand, Nicolas
    Amorin, Sandy
    Noguera, Maria-Elena
    Traverse-Glehen, Alexandra
    Ffrench, Martine
    Baseggio, Lucile
    Felman, Pascale
    Callet-Bauchu, Evelyne
    Brice, Pauline
    Berger, Francoise
    Salles, Gilles
    Briere, Josette
    Coiffier, Bertrand
    Thieblemont, Catherine
    LEUKEMIA & LYMPHOMA, 2014, 55 (08) : 1854 - 1860
  • [32] Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort
    Madsen, Charlotte
    Plesner, Trine Lindhardt
    Bentzen, Hans Herluf
    Jorgensen, Judit
    Sillesen, Ida Blok
    Himmelstrup, Bodil M.
    Josefsson, Par
    Plesner, Torben
    Bennedsen, Tine Litske
    Ludvigsen, Maja
    d'Amore, Francesco A.
    LEUKEMIA & LYMPHOMA, 2020, 61 (11) : 2584 - 2594
  • [33] Identification of a Splenic Marginal Zone Lymphoma Signature: Preliminary Findings With Diagnostic Potential
    Robinson, Jacob E.
    Greiner, Timothy C.
    Bouska, Alyssa C.
    Iqbal, Javeed
    Cutucache, Christine E.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [34] Defining the borders of splenic marginal zone lymphoma: a multiparameter study
    Dufresne, Scott D.
    Felgar, Raymond E.
    Sargent, Rachel L.
    Surti, Urvashi
    Gollin, Susanne M.
    McPhail, Ellen D.
    Cook, James R.
    Swerdlow, Steven H.
    HUMAN PATHOLOGY, 2010, 41 (04) : 540 - 551
  • [35] Significant efficacy of 2-chlorodeoxyadenosine± rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up
    Cervetti, G.
    Galimberti, S.
    Pelosini, M.
    Ghio, F.
    Cecconi, N.
    Petrini, M.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2434 - 2438
  • [36] Recurrent autoimmune hemolytic anemia in splenic marginal zone lymphoma
    Oladiran, Oreoluwa
    Dhital, Rashmi
    Donato, Anthony
    JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2018, 8 (04): : 244 - 245
  • [37] Clinico-biological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy
    Mercadal, Santiago
    Pomares, Helena
    Sancho, Juan M.
    Climent, Fina
    Garcia, Olga
    Encuentra, Maite
    Domingo-Domenech, Eva
    Sorigue, Marc
    Moreno, Miriam
    Oliveira, Ana C.
    Ribera, Josep-Maria
    Fernandez de Sevilla, Alberto
    Gonzalez-Barca, Eva
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (03) : 470 - 473
  • [38] Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)
    Cervetti, G.
    Galimberti, S.
    Sordi, E.
    Buda, G.
    Orciuolo, E.
    Cecconi, N.
    Petrini, M.
    ANNALS OF ONCOLOGY, 2010, 21 (04) : 851 - 854
  • [39] Splenic marginal zone lymphoma and autoimmunity: Report of six cases
    Voinchet, H.
    Etienne, G.
    Ghiringelli, C. -B.
    Pellegrin, J. -L.
    Viallard, J. -F.
    Parrens, M.
    Longy-Boursier, M.
    REVUE DE MEDECINE INTERNE, 2010, 31 (01): : 4 - 11
  • [40] Splenic marginal zone lymphoma: a case report and literature review
    Zhang, Shiyu
    Xuan, Zefeng
    Zhang, Liang
    Lu, Jiahua
    Song, Penghong
    Zheng, Shusen
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)